NEW YORK (GenomeWeb News) – Point-of-care firm SuperNova Diagnostics today announced a co-marketing deal with Concile for a test that assesses "various deficiencies" relating to wellness and chronic diseases.
The terms of the deal gives Concile, a German diagnostic development and distribution firm, the rights to co-market SuperNova's test in Europe. SuperNova will develop and manufacture the test, secure regulatory approvals, and co-market it.
Concile will provide SuperNova upfront payments, milestone development payments, and share revenues for sales within the European Union. SuperNova retains all marketing rights outside of the EU, it said.
Neil Campbell, president and CEO of SuperNova, said in a statement, "The partnership and sales reach of Concile gives us a focused entry into the European market with an established leader and also allows us to build our commercial business into other markets."
Financial terms were not disclosed.
Headquartered in German Town, Md., SuperNova is a development stage firm whose main technology is a nanochemistry-based DNA amplification method it calls AmpCrystal that achieves "ultra-low sensitivity and specificity while not sacrificing a dynamic range of measurements," it said.